ARWR News & Events

Reports Q2 revenue $73.7M, consensus $71.7M. "Arrowhead continues to show strong execution in meeting and exceeding our commercial, R&D, and corporate goals. The company is on extremely strong footing to continue to drive growth in the near-term with numerous opportunities to create long-term shareholder value," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. "We remain focused on a few key areas as being critical sources of sustainable growth for Arrowhead, and we have made tangible advancements across these areas. These include: strengthening our commercial presence to bring REDEMPLO(R) and potentially other cardiometabolic products in the future to the many patients and physicians who need it; continuing to deliver best-in-class in discovery, development, and regulatory capabilities in support of a deep pipeline of RNAi therapeutics capable of silencing genes expressed throughout the body to treat various diseases; and, being strategic and disciplined around pipeline, portfolio, and financial management."

Arrowhead Pharmaceuticals (ARWR) announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (MDGL) for ARO-PNPLA3, Arrowhead's clinical stage RNA interference therapeutic designed to reduce liver expression of patatin-like phospholipase domain containing 3 as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis. PNPLA3 has strong genetic and preclinical validation as a driver of fat accumulation and damage in the livers of patients who carry the I148M mutation. The I148M genetic variant is involved with the underlying pathophysiology and is a known risk factor for hepatic steatosis, steatohepatitis, elevated plasma liver enzyme levels, hepatic fibrosis, and cirrhosis.

Arrowhead Pharmaceuticals announced that the Australian Therapeutic Goods Administration, TGA, has approved Redemplo, a small interfering RNA medicine, as an adjunct to diet to reduce triglyceride levels for adult patients with familial chylomicronemia syndrome, FCS, for whom standard triglyceride lowering therapies have been inadequate. FCS is a severe, rare disease characterized by triglyceride levels that can be orders of magnitude higher than normal, leading to a substantially higher risk of developing acute, recurrent, and potentially fatal pancreatitis. "We are pleased that Redemplo is now the first-ever approved treatment for Australians living with genetic or clinical FCS," said Christopher Anzalone, Ph.D., President and CEO of Arrowhead Pharmaceuticals. "This approval underscores the strength of the clinical data and the ability of our TRiM platform to develop targeted siRNA therapies to potentially reach multiple tissues and disease areas. We believe Redemplo could represent an important medicine for the FCS community in Australia, and we are working to bring this therapy to more patients as quickly as possible."